At 16 weeks , the adjusted mean change in HbA1c from baseline was significantly reduced in the dapagliflozin 2.5 mg twice daily and 5mg twice daily groups versus placebo ( -0.52 vs. -0.30 % , p = 0.0106 and -0.65 % vs. -0.30 % , p < 0.0001 ) .